Spinal cord pathology in chronic traumatic encephalopathy with motor neuron disease by Fry, Brian
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2014
Spinal cord pathology in chronic
traumatic encephalopathy with
motor neuron disease
https://hdl.handle.net/2144/14671
Boston University
	   	   	  
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
 
SPINAL CORD PATHOLOGY IN  
CHRONIC TRAUMATIC ENCEPHALOPATHY  
WITH MOTOR NEURON DISEASE 
 
 
 
by 
 
 
 
 
BRIAN FRY 
 
B.A., Bowdoin College, 2010 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2014  
	   	   	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2014 by 
 BRIAN TOSHIRO FRY 
 All rights reserved  
	   	   	  
Approved by 
 
 
 
 
First Reader   
 Gwynneth D. Offner, Ph.D. 
 Director, MA in Medical Sciences Program 
 Associate Professor of Medicine 
  
 
Second Reader   
 Ann McKee, M.D.  
 Professor of Neurology and Pathology 
 Director, Neuropathology Core 
 
 
Third Reader   
 Thor Stein, M.D., Ph.D. 
 Assistant Professor of Pathology and Laboratory Medicine 
 Associate Director, Neuropathology Core 
  
 
 
	  	   iv 
ACKNOWLEDGEMENTS 
 
I’d like to acknowledge and thank my mentors Dr. Ann McKee, Dr. Thor Stein, and Dr. 
Victor Alvarez for supporting me in throughout the writing of this thesis and giving me 
the opportunity to be a part of this exciting research. I’d also like to thank my wonderful 
advisor, Dr. Gywnneth Offner, for all of her help and support throughout the MAMS 
program, the medical school application process, and the completion of this paper—she 
has played a vital role in my survival over the past two years.  
 
  
	  	   v 
SPINAL CORD PATHOLOGY IN CHRONIC TRAUMATIC 
ENCEPHALOPATHY WITH MOTOR NEURON DISEASE 
BRIAN FRY 
ABSTRACT 
 Chronic Traumatic Encephalopathy (CTE) is a neurodegenerative disease caused 
by repetitive head trauma and mild traumatic brain injuries (mTBIs) and has been 
associated with contact sports such as football, boxing, and ice hockey. CTE is a slowly 
progressing neurological disease that is often clinically associated with symptoms of 
memory loss, decline in cognitive function, behavioral changes such as increased 
impulsivity and aggression, and/or suicidal thoughts. Advanced stages of the disease 
present with more severe neurological changes such as dementia, speech and gait 
abnormalities, and parkinsonism.  
 Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig Disease) is a 
progressive and fatal neurodegenerative disease characterized by motor neuron loss and 
corticospinal tract degeneration. While 90-95% of ALS cases are sporadic in nature, 
many genetic mutations have been identified that contribute to familial forms of the 
disease. The etiology of sporadic ALS is unknown but it is likely caused by a complex 
interaction of various genetic and environmental risk factors. Epidemiological evidence 
suggests that one such risk factor is brain trauma, the main risk factor associated with the 
development of CTE.  
 In this study the spinal cord tissue of twelve athletes diagnosed with CTE who 
also developed a progressive motor neuron disease and showed symptoms of profound 
	  	   vi 
muscle weakness, atrophy, spasticity, and fasciculations several years before death was 
examined. The spinal cord tissue from these 12 CTE cases with motor neuron disease 
(CTE+MND) was compared to the spinal cord tissue of 10 sporadic ALS control cases.  
Results showed a difference in frequency of tau pathology between the two 
disease cohorts, as one-third of CTE+MND cases and none of the ALS cases showed tau 
immunoreactivity. In addition, TDP-43 immunoreactivity was present in every 
CTE+MND case but one and was present in all ALS cases. Motor neuron inclusions were 
positive for both FUS and p62 in both cohorts, and no distinct differences were observed 
cystatin C pathology. 
Overall, this suggests that the spinal cord inclusions in CTE+MND have a similar 
composition to sporadic ALS. However, there is an increased frequency of tau pathology 
in CTE+MND though this result did not reach statistical significance in this study.  
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INTRODUCTION 	  
Concussions and Traumatic Brain Injury (TBI) 
 While no uniform definition for concussion currently exists, the consensus 
statement from the 2012 International Conference on Concussion in Sport held in Zurich 
defines a concussion as a pathophysiological process resulting in functional neurological 
impairments as a consequence of forceful biomechanical impacts directly on or 
transmitted to the head, neck, or face (McCrory et al., 2013). Brain injury follows from 
rapid acceleration and deceleration mechanics that occur during a traumatic impact and 
can include linear, translational, and/or rotational forces, with translational and rotational 
forces thought be the most significant contributors toward the severity of injury (Kimpara 
and Iwamoto, 2012; McCrory et al., 2013; Zhang et al., 2004). Symptoms vary from 
person to person, but they typically include some signs of physical injury (such as 
headache, dizziness, or nausea), signs of cognitive impairment (such as memory loss, 
difficulty concentrating, or confusion), and/or behavioral changes (such as emotional 
lability, fatigue, or anxiety) (Jordan, 2013). While conditions such as second impact 
syndrome (SIS) have thrown the media spotlight on the immediate dangers of 
concussions and traumatic brain injuries, illnesses such as Chronic Traumatic 
Encephalopathy (CTE) and chronic post concussion syndrome (CPCS) have elucidated 
the possible long-term dangers of head trauma.  
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Epidemiology of Concussion and Brain Injury 
 While figures vary, it’s estimated that 1.6-3.8 million sports-related TBIs occur 
annually in the United States alone (Langlois et al., 2006). However, this number is likely 
an underestimate of the overall incidence of concussions as it does not include data from 
outpatient facilities, the U.S. Military, nor those who choose not to seek medical care 
after injury (Coronado et al., 2012). Though the incidence of concussion seems to have 
been increasing in recent years, it may be in part because of better concussion awareness, 
education, and diagnosis (Daneshvar et al., 2011). Significant risk factors for sustaining a 
sports-related concussion include having a history of a previous concussion, playing in a 
match vs. practice, and type of sport played (i.e. collision vs. non-collision). Lower level 
risk factors include being younger in age, being female, and level of play (i.e. high 
school, college, or professional), among others (Abrahams et al., 2013).  
The media has brought the health concerns over sports-related brain injury into 
the public eye with its recent coverage of the ex-football players’ 2013 settlement with 
the National Football League regarding the dangers of on-field head injuries, as well as 
the airing of the 2013 PBS Frontline documentary “League of Denial,” which provides an 
in depth analysis of head trauma in the NFL (and is based off of the book by the same 
title). Although much exciting research is being done in the field of traumatic brain 
injury, we still do not have a definitive diagnostic tool to assess concussions nor do we 
currently have a sophisticated treatment protocol for people who suffer these injuries. 
Diffuse tensor imaging (DTI) and functional magnetic resonance imaging (fMRI) are 
promising tools that can help detect subtle injuries within the brain and may aid in 
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concussion diagnosis; however the standard treatment protocol typically only involves 
immediate removal from physical and cognitive stimuli until symptoms resolve (Jordan, 
2013). While some physicians will prescribe medications to treat severe symptoms 
associated with brain injury (headache, dizziness, anxiety), treatment does not currently 
exist to repair and/or reverse any damage done to the brain at the molecular level.  
 
Second Impact Syndrome (SIS) 
 SIS is a rare but potentially fatal condition that occurs when an athlete receives a 
second traumatic head injury while still symptomatic from a previous concussion. The 
second traumatic hit leads to diffuse brain swelling, cerebral edema, and eventually brain 
herniation, which is thought to arise from the loss of autoregulation of cerebral blood 
flow (Jordan, 2013). The exact frequency of SIS is unknown but one U.S. study reported 
17 deaths from SIS over a 30-year period (Thomas, 2011). Given the mortality and the 
severity of the injuries associated with the syndrome, SIS is a major concern for athletes 
who suffer from an acute concussion and necessitates a conservative approach to 
recovery before returning to a contact sport such as American football or ice hockey.  
 
Chronic Post Concussion Syndrome (CPCS) 
 CPCS is an uncommon condition in which an athlete experiences long-term or 
permanent post-concussion symptoms following a traumatic brain injury. While no 
consensus criteria exist for CPCS, the term generally refers to acute post-concussion 
symptoms that last longer than one year as a result of a single concussive event (Jordan, 
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2013). Common symptoms include headache, dizziness, impaired attention, memory 
problems, executive dysfunction, irritability, and depression and often result in the athlete 
retiring from sport. While the pathological mechanisms underlying CPCS are unknown, it 
represents a condition that results directly from a single concussive event, thus clearly 
distinguishing it from neuropathological diseases such as Chronic Traumatic 
Encephalopathy and Alzheimer’s disease, where repetitive head trauma over a period of 
years or even decades may trigger neurodegeneration.   
 
Head Trauma and Neurodegenerative Disease 
 There is mounting evidence for a causal link between head trauma and the 
development of neurodegenerative diseases such as Chronic Traumatic Encephalopathy, 
Alzheimer’s disease, Parkinson’s disease, ALS, and frontotemporal dementia (Gardner 
and Yaffe, 2014; Walker and Tesco, 2013). Studies suggest that levels of amyloid-beta 
protein (the pathological protein most often associated with Alzheimer’s disease) are 
raised following acute brain trauma and it’s been shown that pathological 
hyperphosphorylated tau accumulation (the pathological protein most often associated 
with CTE) is significantly higher in individuals with a history of repetitive head trauma 
(Mielke et al., 2014; McKee et al., 2013). Due to the nature of this thesis, 
epidemiological, clinical, and pathological information will only be given for CTE and 
ALS.  
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Chronic Traumatic Encephalopathy (CTE) Overview 
 CTE is a slowly progressing neurodegenerative disease found in individuals with 
a history of repetitive brain trauma. The origins of CTE can be traced back to 1928 when 
a New Jersey pathologist, Harrison Martland, described a condition called “punch 
drunk,” a set of neurodegenerative symptoms found in boxers resulting from repeated 
blows to the head (Martland, 1928). Although the condition was originally coined 
“dementia pugilistica” in 1937 by Millspaugh, the realization that sports other than 
boxing were associated with its development led to the use of “progressive traumatic 
encephalopathy” in 1949 followed by CTE in 1957 (Millspaugh, 1937; Critchley, 1949, 
1957).  
 Because head trauma is inherent in the nature of most contact sports, CTE has 
been found mostly in the brains of former amateur and professional boxers, wrestlers, 
American football players, ice hockey players, and rugby players; however, the disease 
has also been found in the brains of military explosives specialists, one former 
professional baseball player, and most recently in the brain of a former collegiate level 
soccer player (McKee et al., 2013; Mohney, 2014). It’s important to note that all reported 
neuropathologically confirmed cases of CTE have had exposure to repetitive brain 
trauma during life; however, not all subjects with a history of repetitive brain trauma 
develop CTE. This indicates that additional genetic and environmental risk factors likely 
have a role in the neuropathogenesis of the disease (Stern et al., 2013).  
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Epidemiology of CTE 
 Unfortunately, the body of published literature on CTE is still quite small and thus 
epidemiological data regarding its prevalence in the population is not available at the 
time of this writing. While data is available on the number of confirmed CTE cases from 
the Sports Legacy Institute-Boston University CTE Brain Bank, the total sample size and 
inherent selection bias prevent the data from being generalized to a larger population. 
Larger scale prospective studies are being done at the Boston’s University’s CTE Center 
that will eventually shed some light on CTE’s prevalence, particularly in professional 
American football players.  
 
Clinical Presentation of CTE 
Generally speaking, early symptoms associated with CTE include aggression, 
irritability, depression, impulsivity, short-term memory loss, and heightened suicidality 
that typically begin eight to ten years after experiencing repetitive traumatic brain injury. 
Later stages of the disease show symptoms that reflect more serious neuropathological 
changes and include dementia, speech and gait abnormalities, and parkinsonism (McKee 
et al., 2009). No methods currently exist to diagnose CTE in living subjects—the disease 
can only be confirmed via post-mortem neuropathological evaluation of a subject’s brain 
tissue. Because the clinical symptoms of CTE overlap with several other 
neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and 
frontotemporal dementia, the discovery of a promising biomarker for the disease is vital 
	  7	  
 
in order to help distinguish CTE’s clinical presentation and the ability to diagnose the 
disease during life.  
 Recently, Stern and colleagues published the largest analysis of clinical symptoms 
associated with CTE and suggested that there are two distinct clinical presentations of 
CTE: one variant that initially displays behavioral or mood changes and another that 
initially displays cognitive impairment (Stern et al., 2013). The behavior/mood group 
presented with symptoms at a significantly younger age and was also more emotionally 
explosive, out of control, physically and verbally violent, and depressed than the 
cognition group. Stern and colleagues also highlighted the trend that subjects in the 
behavior/mood group almost always developed cognitive impairments at some point in 
time but that significantly fewer subjects in the cognition group demonstrated behavior 
and mood changes during the course of the disease. While all subjects in the cognition 
group were reported to have impaired episodic memory, approximately 25% of the 
behavior/mood group did not have reported memory difficulties.  
While it’s uncertain how these differences reflect neuropathological changes, 
Stern and colleagues suggest that it’s possible these differing symptoms stem from 
pathological changes focused in different parts of the brain during the course of the 
disease. Early development of tau pathology in the locus coeruleus and amygdala could 
play a role in the behavioral and mood changes reported for the younger group, while 
degeneration in the hippocampus and frontal cortex could play a role in the memory and 
executive dysfunction in the cognition group (Stern et al., 2013; McKee et al., 2013). 
Stern and colleagues also pointed out that the many of the symptoms found in the 
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younger behavioral/mood group could be due to persistent postconcussion syndrome with 
unresolved or progressive axonal damage resulting from the subjects’ initial head trauma. 
While selection bias and small sample size in the 2013 Stern study limit the 
generalizability of its conclusions to the greater CTE population, its findings certainly 
merit further investigation into clarifying the clinical presentation of CTE. 
 
Neuropathology of CTE 
 The hallmark pathological feature of CTE is the widespread deposition of 
hyperphosphorylated tau (p-tau) in the form of neurofibrillary tangles (NFTs). Normal 
tau proteins are intracellular and function to stabilize neuronal microtubules, particularly 
within axons. Upon becoming phosphorylated, tau will dissociate from the microtubules 
and form pathological protein aggregates known as NFTs (and eventually lead to cell 
death). Recent evidence suggests that pathobiology of forming NFTs may be more 
harmful than the resulting NFTs themselves, as cellular abnormalities associated with 
their formation include a disruption in autophagy, vesicular trafficking mechanisms, 
axoplasmic transport, neuronal polarity, and the secretion of tau into the extracellular 
space (Gendreau and Hall, 2013).  
While the clinical presentation of CTE may be confused with other 
neurodegenerative diseases, the neuropathological changes of CTE are clearly distinct 
from other tauopathies such as Alzheimer’s disease and frontotemporal lobar 
degeneration (McKee et al., 2013). According to McKee and colleagues, gross 
neuropathological features of CTE include atrophy of many brain structures involved in 
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normal cognitive and behavioral functioning, ventricular dilation, and septal 
abnormalities such as a splayed or even absent septum pellucidum. Additionally, 
extensive p-tau pathology is found in frontal and temporal cortices, preferentially 
clustered around small vessels at the depths of cerebral sulci, as well as in major limbic 
and central brain region structures such as the thalamus and hippocampus. There is also 
severe degeneration of axons and white matter tracts throughout the brain and brainstem. 
Most CTE cases also show evidence of TAR DNA-binding protein 43 (TDP-43) 
pathology with a relative absence of beta amyloid (the pathological protein most 
associated with Alzheimer’s disease and aging) (McKee et al., 2013).  
 In the same paper, McKee and colleagues separated the spectrum of CTE into 
four progressive stages. A summary of the gross and microscopic features of each stage 
can be found in Table 1 at the end of this section. The mildest stage of CTE (stage I) was 
grossly characterized by occasional mild ventricular enlargement with other gross 
neuropathological features and brain weights not significantly different than those of 
normal brains. Microscopically, stage I CTE was characterized predominantly by discrete 
areas of peri-vascular p-tau NFTs and astrocytic tangles, predominantly located in the 
depths of cerebral sulci. Scattered and distorted axonal varicosities were found in the 
frontal cortex as well as subcortical white matter and deep white matter tracts of the 
diencephalon. Additionally, roughly half of the stage I cases examined showed TDP-43 
immunopositive neurites in the frontal subcortical white matter and fornix.  
 Gross pathology of stage II CTE cases remained fairly similar to stage I cases and 
included mild ventricular enlargement; however, roughly one third of cases showed a 
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small cavum septum pellucidum (a splaying of the membrane that separates the lateral 
ventricles), roughly one-third of cases showed pallor of the locus coeruleus and 
substantia nigra, and one case showed severe atrophy of one mammillary body. 
Microscopically, multiple epicenters of p-tau NFTs and astrocytic tangles were found in 
the depths of cerebral sulci. In addition, p-tau NFTs were found in superficial layers of 
the cortex with and moderate deposition of p-tau NFTs in the nucleus basalis of Meynert 
and locus coeruleus. Very mild deposition of p-tau NFTs was found in medial temporal 
lobe structures including the hippocampus and entorhinal cortex as well as in midbrain 
structures including the substantia nigra and the dorsal and median raphe nuclei. 
Distorted axonal varicosities were found in frontal and temporal cortices as well as white 
matter tracts. About 80% of the stage II cases examined showed TDP-43 
immunopositivity, a minority of which showed severe TDP-43 pathology in widespread 
regions of the brain and spinal cord.  
 Grossly, stage III CTE cases showed mild cerebral atrophy with moderate 
ventricular dilation. A little over 40% of brains showed septal deformities including 
cavum septum pellucidum, septal tears, or a total absence of the septum entirely. A larger 
percentage of cases showed moderate depigmentation of the locus coeruleus and mild 
depigmentation of the substantia nigra (~60% and ~40%, respectively). Other common 
gross pathological features included shrinkage of the mammillary bodies and thalamus, a 
distinct convex shape of the medial thalamus, and thinning of the hypothalamic floor and 
corpus callosum. Microscopically, extensive p-tau pathology was found in medial 
temporal lobe structures (entorhinal cortex, hippocampus, and amygdala) and was 
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prominently spread in regions of the frontal, temporal, parietal, insular, and septal 
cortices, diencephalon, brainstem, and spinal cord. Severe axonal loss and distortions 
were found in subcortical white matter in the frontal and temporal cortices. A similar 
proportion of cases displayed TDP-43 pathology as compared to stage II cases.  
 Cases categorized with the most severe CTE stage (stage IV) showed increased 
cerebral atrophy as well as significant shrinkage of the medial temporal lobe, thalamus, 
hypothalamus, and mammillary bodies. In addition to having significantly smaller mean 
brain weights than earlier stage CTE, the majority of stage IV brains showed increased 
ventricular dilation, a sharply concave shape of the third ventricle, and more exaggerated 
septal abnormalities (cavum, perforations, or complete absence). All stage IV cases 
showed depigmentation of the locus coeruleus and substantia nigra where it could be 
assessed. Microscopically, stage IV cases showed severe neuronal loss and gliosis in the 
cerebral cortex, hippocampal sclerosis, and severe p-tau pathology widely distributed 
throughout the cerebrum, diencephalon, basal ganglia, brainstem, and spinal cord. Stage 
IV cases also showed severe axonal loss and distortions as well as the most severe TDP-
43 pathology. TDP-43 positive neurites and inclusions were found in the cerebral cortex, 
medial temporal lobe, diencephalon, basal ganglia, brainstem, and less regularly in the 
spinal cord (McKee et al., 2013).  
 
Motor Neuron Disease Overview 
 Although many disorders fall under the category of motor neuron diseases, when 
the term is used in a singular fashion (i.e. ‘motor neuron disease’) it generally refers to 
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amyotrophic lateral sclerosis (ALS). ALS, sometimes referred to as Lou Gehrig’s disease 
after the famous New York Yankees baseball player, is the most common of motor 
neuron diseases among adults. It is a progressive and fatal disease that involves the 
degeneration of both upper and lower motor neurons in the brain and spinal cord.  
 
Epidemiology of ALS 
 It’s estimated that the worldwide prevalence of ALS is approximately 5-7 people 
per 100,000 while the incidence is approximately 2 per 100,000 people (Chiò et al., 
2013). About 5 to 10% of ALS cases are familial (fALS) while the remainder are 
sporadic (sALS). The incidence of sALS is higher in men than in women (by a ratio of 
about 1.5:1) and the mean onset of sALS is around 60 years of age, though about a 
quarter of patients present under the age of 50 years (Greenfield et al., 2008). The median 
survival varies but is typically around 3 years after the onset of symptoms. Longer 
survival has been associated with limb onset, younger age at onset, better motor function, 
higher breathing capacity, stable weight, and longer intervals of time between symptom 
onset and diagnosis of the disease (Gordon, 2013). While some research suggests that 
there may be an association between head trauma and ALS, other studies dispute this 
suspicion and thus stronger evidence is needed before claiming that head trauma is 
indeed a true risk factor for the development of the disease (Walker and Tesco, 2013; 
Armon and Nelson, 2012). 
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Genetics and ALS 
 Approximately 60% of inherited ALS cases are associated with known genetic 
mutations, 20% of which are caused by mutations in the copper-zinc superoxide 
dismutase 1 (SOD1) gene (Gordon, 2013). The SOD1 gene encodes an enzyme that 
destroys free superoxide radicals in the body, but when mutated the resultant protein 
forms toxic gain-of-function	  aggregates that cause neuronal loss. There’s very strong 
evidence to suggest pathogenic roles for other gene mutations such as transactive 
response DNA binding protein 43-kDa (TDP-43), fused in sarcoma protein (FUS), and 
C9ORF72 protein (chromosome 9 open reading frame 72), among others (Gordon, 2013). 
In addition, genes encoding proteins involved in the proteosomic or autophagic clearance 
systems, such as UBQLN2 and SQSTM1, have been associated with fALS (Verma and 
Tandan, 2013).  
 
Clinical Presentation of ALS 
 ALS leads to the progressive degeneration of the upper motor neurons in the 
cerebral cortex as well the lower motor neurons in the medulla and anterior horn of the 
spinal cord. The general effect is progressive muscle weakness and atrophy that leads to 
death, usually from respiratory failure as the diaphragm and intercostal muscles lose the 
ability to function properly (Gordon, 2013). Lower motor neuron loss leads to muscle 
fasciculations, cramps, atrophy, and as a result, marked muscle weakness. Loss of upper 
motor neurons is associated with spasticity, hyperreflexia, and modest muscle weakness. 
Upper motor neuron loss can clinically manifest through the Babinski sign where a 
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patient has an extension reflex upon the sole of his/her foot being stroked with a blunt 
instrument. Emotional lability is another sign of upper motor neuron dysfunction, where a 
patient undergoes involuntary and uncontrollable episodes of crying, laughter, or other 
emotions.  
 ALS presents in a clinically heterogeneous manner even among family members 
with the disease; variations in speed of progression of the disease as well as in the origin 
of clinical symptoms can make it very difficult to clinically diagnose at its early stages. In 
addition, cognitive impairment and behavioral disturbances can also manifest in patients 
with the disease.  
 ALS begins peripherally in a patient’s limbs (usually in the arms) in about two-
thirds of cases. Symptoms typically include foot drop, difficulty walking, loss of hand 
dexterity, or weakness when lifting the arms, and usually manifest focally and 
unilaterally. Bulbar-onset ALS, which is more prevalent in elderly women, carries a 
worse prognosis and follows the progression of symptoms from dysarthria (difficulty 
speaking), dysphagia (difficulty swallowing), sialorrhea (hypersalivation), to eventual 
malnutrition and anarthria (inability to speak) (Gordon, 2013).  
 Cognitive impairment was originally thought to be uncommon in ALS until fairly 
recently. Evidence suggests that roughly 50% of patients with ALS will present clinically 
with cognitive impairment and that 15% of ALS patients have severe cognitive 
impairment consistent with frontotemporal dementia (Phukan et al., 2007).  
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Neuropathology of ALS 
 While loss of upper and lower motor neurons is the hallmark pathological sign of 
ALS, no widely used system currently exists to stage the disease in a similar manner to 
that of CTE. Dr. John Trojanowski and colleagues published a preliminary staging 
system based on TDP-43 pathology and its theorized progressive spread throughout 
disease (Brettschneider et al., 2013). If widely adapted it would prove to be the first 
staging system that could be used in conjunction with neuropathological diagnosis of 
ALS and would constitute a major step towards understanding disease progression 
mechanisms. Because the staging is only preliminary, this thesis will only summarize the 
guidelines in brief detail. 
 According to Trojanowski and colleagues, stage 1 ALS cases were characterized 
by the presence of TDP-43 immunoreactive inclusions in the agranular motor cortex, 
motor neurons in the anterior horn of the spinal cord, and in bulbar motor neurons of 
cranial nerves V, VII, and X-XII. Stage 2 involved the pathology from stage 1 plus some 
involvement of the prefrontal cortex, reticular formation (both parvocellular and 
magnocellular portions), and in precerebellar nuclei (inferior olivary complex). Stage 3 
presented with more severe TDP-43 pathology in the prefrontal cortex as well as 
involvement of the basal ganglia, with a particular focus within the striatum. Finally, 
TDP-43 pathology in stage 4 spread to the transentorhinal and entorhinal cortices as well 
as the hippocampal formation (Brettschneider et al., 2013).  
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Chronic Traumatic Encephalopathy + Motor Neuron Disease (CTE+MND) 
 As mentioned previously, repetitive head trauma is associated with both the 
development of CTE and ALS (though to much lesser degree for ALS). McKee and 
colleagues published a potentially ground breaking study in 2010 that provides evidence 
for a linkage between CTE and ALS (McKee et al., 2010). Dr. McKee and her 
collaborators reviewed the cases of 12 athletes with CTE, 3 of whom also had signs and 
symptoms of Motor Neuron Disease during their lifetimes. The study compared the brain 
and spinal cord pathology of these 3 cases (referred to as CTE+MND for Chronic 
Traumatic Encephalopathy with Motor Neuron Disease) with the pathology of the CTE-
only cases, as well as age- and sex- matched ALS-only cases and normal control brains.  
 In the brains of cases with CTE but without MND (n=9), pathological changes of 
CTE were present (p-tau pathology in the frontal, temporal, and insular cortices, 
diencephalon, basal ganglia, and brainstem). 7 of the 9 cases displayed extensive TDP-43 
immunoreactivity, with TDP-43 pathology found in the frontal and temporal cortices, 
insula, subcortical white matter, brainstem, amygdala, hippocampus, caudate, putamen, 
thalamus, and hypothalamus. In the 5 cases with spinal cord tissue available for analysis, 
all 5 showed tau-immunoreactive neurites and NFTs in the lateral, dorsal, and anterior 
horns of the spinal cord, while only 2 of 5 cases showed TDP-43 pathology in the form of 
occasional TDP-43 positive ring neurites.  
 Macroscopically, the brain and spinal cord tissue of athletes with CTE+MND 
(n=3) did not differ from the CTE-only cases with exception of atrophy of the ventral 
roots of the spinal cord. All 3 cases showed characteristic p-tau pathology consistent with 
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CTE but had TDP-43 pathology in a far greater density than that found in the CTE-only 
brain and spinal cord tissue. In the brains of CTE+MND athletes, TDP-43 pathology was 
concentrated in the motor cortex. General features of the CTE+MND cases included 
marked myelin and axonal loss with astrocytosis in the medullary pyramids and 
corticospinal tracts throughout the spinal cord along with moderate to profound anterior 
horn cell loss with atrophy and gliosis of the ventral roots. Tau-positive pathology was 
found in the posterior, lateral, and ventral horns, frequently surrounding degenerating 
anterior horn cells.  
 Of the 12 sporadic ALS cases examined, rare tau-positive neurites were found in 
only one case while TDP-43 pathology was present and abundant in every case. In the 12 
control cases examined, rare tau-positive neurites were found in the ventral horn of 4 
cases while no TDP-43 pathology was observed in any of the 12 cases.  
 The findings of the 2010 McKee study provided promising early evidence that a 
distinctive and widespread TDP-43 pathology is associated with CTE (7 of 9 CTE-only 
cases showed extensive TDP-43 pathology) and that in some individuals the pathology 
may become so severe that it involves the spinal cord and manifests clinically as Motor 
Neuron Disease. McKee and colleagues noted that the lack of tau pathology in the ALS 
control cases, combined with its absence in descriptive literature surrounding Motor 
Neuron Disease provides fairly convincing evidence that the CTE+MND cases described 
are not a rare tau-variant form of MND. In addition, the widespread TDP-43 pathology 
reported in most CTE cases provides evidence against the coincidental comorbidity of 
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both CTE and ALS and rather points towards some sort of continuum of TDP-43 
pathology within all CTE cases.  
 
Specific Aims and Objectives 
 The findings of the 2010 McKee paper provided the motivation to look further 
into the descriptive pathology of known CTE+MND cases. Of specific interest was the 
pathology within the anterior horn of the spinal cord, an area that is highly affected by 
neurodegeneration in Motor Neuron Disease. A comparative analysis of the pathology in 
this region among CTE+MND, CTE, ALS, and control cases would provide further 
information to elucidate whether the observed CTE+MND have a distinct and separate 
pathology from both CTE and ALS, or whether they are unique instances of comorbid 
CTE and ALS pathology.  
Currently in 2014, there are an additional 9 CTE+MND cases to examine along 
with the 3 cases cited in 2010. This thesis is a preliminary report of qualitative findings 
associated with a larger effort to describe and quantify (when possible) the pathology of 
CTE+MND and its distinguishing features in comparison to CTE, ALS, and control 
cases.
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METHODS	  
Subjects 
 Spinal cord slides from the 12 pathologically verified CTE+MND cases were cut 
and stained from spinal cord tissue obtained via the brain donation program at the CTE 
Center at Boston University’s Alzheimer’s Disease Center and the Sports Legacy 
Institute-Boston University Brain Bank. Brain and spinal cord tissue for each case was 
obtained through written consent forms for brain and spinal cord donation signed by the 
donor’s legal next of kin. Institutional review board approval for brain donation was 
obtained through the Boston University Alzheimer’s Disease Center, Boston University’s 
Center for the Study of Traumatic Encephalopathy (now called the CTE Center at Boston 
University), and the Edith Nourse Rogers Bedford Veterans Affairs Medical Center. 
Post-mortem clinical information for each case was obtained through analysis of the 
donor’s medical records (per consent of the legal next of kin) as well as interviews with 
the donor’s close family members. Institutional review board approval for medical record 
review, family interviews, and neuropathological evaluation was obtained through the 
Boston University School of Medicine. Dr. Ann McKee of Boston University’s School of 
Medicine performed the neuropathological evaluation while Dr. Robert Stern of Boston 
University’s School of Medicine performed the clinical interviews and evaluation for 
each case.  
 Spinal cord slides for the 10 ALS control cases were cut and stained from paraffin 
embedded tissue blocks received from the University of Wisconsin School of Medicine.   
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Choice of Immunohistochemical Stains 
 In this initial analysis, 5 different antibodies were chosen to stain across all of 
spinal cord slides for the pathological versions of the following proteins: tau (AT8 
antibody), TDP-43, FUS, nucleoporin p62 (p62), and cystatin C.  
Inclusion of tau and TDP-43 in this analysis was critical as the pathological 
versions of these proteins are commonly associated with CTE and ALS, respectively. 
FUS and p62 are proteins that have both been found to localize to pathological inclusions 
within motor neurons in ALS (Lagier-Tourenne, 2010; Safa, 2011). Cystatin C is another 
protein of interest as its pathological aggregates have also been found to localize to 
degenerating motor neurons in ALS (Okamoto et al., 2008).  
  
Immunohistochemical Preparation 
 Spinal cord tissue was processed and embedded in paraffin wax with a Sakura 
Tissue-Tek Tissue Embedding Console System. 10 µm sections were then cut from the 
paraffin wax embedded tissue blocks with a Leica RM2135 microtome and individually 
mounted on glass slides. Immunohistochemistry staining was performed following the 
standard lab protocol in Dr. Ann McKee’s laboratory based out of the Edith Nourse 
Rogers Bedford V.A. Medical Center, which is described in detail below.  
Cut paraffin sections were de-paraffinized in xylene for 10 minutes, repeated 3 
times, then transferred into absolute ethanol for 2 minutes, repeated twice. Sections were 
then immersed in methanol and hydrogen peroxide for 30 minutes, transferred into 95% 
ethanol for 2 minutes, and then washed under running tap water for 5 minutes. Tissue 
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was then pre-treated for antigen retrieval per manufacturer guidelines (if necessary, see 
Table 2 below for pretreatment information) followed by a wash in running tap water for 
an additional 5 minutes. Sections were then transferred into phosphate buffered saline 
(PBS, pH 7.4) then blocked with ScyTek superblock buffer (ScyTek, Logan, UT 
#AAA500) for 5 minutes. The sections were then covered with the desired antibody (see 
Table 2 for complete list) and incubated at 4° C overnight. After allowing the sections to 
cool back to room temperature, they were rinsed with PBS (repeated 3 times for a total of 
10 minutes) and then incubated for 30 minutes at room temperature with ScyTek Anti-
polyvalent Biotinylated Secondary Antibody (#ABN500), followed by an additional PBS 
rinse (3 times, 10 minutes total). Sections were then treated with ScyTek Horseradish 
Peroxidase (#ABL500) and incubated for 30 minutes at room temperature, followed by a 
rinse with PBS (3 times 10 minutes total). Sections were then treated with 3-amino-9-
ethylcarbazole (AEC) substrate (containing 20 µL ScyTek chromogen #ACD030 in 1ml 
buffer #ACE500) until well developed and rinsed in distilled water followed by running 
tap water for 5 minutes. Sections were then counterstained in Gill Hematoxylin (Vector 
Laboratories, Burlingame, CA, H-3401), washed in running water for 5 minutes, 
immersed in PBS for 2 minutes, then washed again in running water for an additional 5 
minutes. Sections were then covered with a ScyTek aqueous mounting medium 
(#AML500), dried at room temperature overnight (or until completely dry). Finally, 
sections were immersed in xylene and then cover-slipped with consul-mount (Thermo 
Scientific, Tewksbury, MA, #9990440). See Table 2 below for information on each of the 
antibodies used.  
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Table 2: Antibody Information for Immunohistochemical Staining 
 
Antibody Manufacturer Dilution Pretreatment 
AT8 (tau) Thermo Scientific 1:2,000 No pretreatment 
Cystatin C Millipore 1:2,000 HIER citrate buffer pH 
6.0 
FUS Proteintech Group 1.75µL/mL HIER citrate buffer pH 
6.0, 10 mins 
p62 BD Biosciences 1:1,0000 HIER tris-buffered saline 
(TBS) pH 9.0, 15 mins  
TDP-43 Cosmobio USA 1:2,000 88% formic acid, 2 mins 
 
 
Analysis 
 A qualitative analysis and semi-quantitative analysis of the pathology in the 
anterior horns of the spinal cord of both CTE+MND cases and pure ALS cases was 
performed. Each available spinal cord section from each slide was examined in the 
anterior horn at 200x magnification. For each stain, the presence of a single 
immunoreactive intracellular inclusion, extracellular inclusion, or neuritic thread within 
any anterior horn of a specific section was given a grade of mild (+). The presence of two 
to nine of such immunoreactive signs was given a grade of moderate (++), and ten or 
greater immunoreactive signs was given a grade of severe (+++). Cases without any 
immunoreactivity for a particular stain were marked as negative (-) (see Table 3 for 
summary). For cases with multiple sections of spinal cord available for analysis on a 
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single slide, the most advanced grade of immunoreactivity was taken as representative for 
the entire case. Photo examples of each severity grade were taken using SPOT Basic 
Image Capture software. Victor Alvarez M.D. of the Boston University School of 
Medicine and the Edith Nourse Rogers Bedford V.A. Medical Center helped to confirm 
the grade of pathology severity for each case. 
 
Table 3: Pathology Grading Scale for Anterior Horn of Spinal Cord 
 
Pathological Grade Number of immunoreactive signs (intracellular/extracellular 
inclusions, neuritic threads) present in anterior horn 
Negative (-) 0 
Mild (+) 1 
Moderate (++) 2-9 
Severe (+++) 10+ 
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RESULTS  	   A	  total	  of	  12	  CTE+MND	  cases	  and	  10	  sporadic	  ALS	  cases	  were	  analyzed	  (see	  Tables	  4	  and	  5).	  The	  average	  age	  at	  death	  was	  48.4	  years	  for	  the	  CTE+MND	  cohort	  and	  56.9	  years	  for	  the	  ALS	  cohort.	  All	  CTE+MND	  subject	  and	  eight	  of	  ten	  ALS	  subjects	  were	  male.	  While	  no	  data	  was	  available	  for	  athletic	  history	  in	  the	  ALS	  cohort,	  nine	  of	  the	  CTE+MND	  subjects	  had	  played	  high	  school,	  college	  or	  professional	  football,	  one	  subject	  had	  played	  college	  soccer,	  and	  two	  subjects	  had	  boxed	  professionally.	  Mild,	  moderate,	  and	  severe	  immunoreactivity	  were	  observed	  for	  every	  stain	  with	  the	  exception	  of	  cystatin	  C,	  where	  only	  moderate	  and	  severe	  immunoreactivity	  were	  observed	  (see	  Figs.	  1,	  2,	  and	  3).	  	  Four	  of	  12	  CTE+MND	  cases	  displayed	  tau	  immunoreactivity.	  Of	  those	  cases	  one	  was	  given	  a	  mild	  grade,	  two	  were	  given	  a	  moderate	  grade,	  and	  one	  was	  given	  a	  severe	  grade.	  No	  tau	  immunoreactivity	  was	  observed	  in	  any	  of	  the	  ALS	  cases.	  TDP-­‐43	  immunoreactivity	  was	  observed	  in	  11	  of	  12	  CTE+MND	  cases	  and	  in	  all	  10	  ALS	  cases	  with	  a	  roughly	  similar	  distribution	  of	  severity	  grades	  within	  each	  disease	  cohort.	  FUS	  immunoreactivity	  was	  observed	  in	  all	  12	  CTE+MND	  cases	  and	  in	  8	  of	  10	  ALS	  cases,	  though	  2	  CTE+MND	  cases	  were	  graded	  with	  severe	  pathology	  while	  grading	  was	  limited	  to	  mild	  or	  moderate	  in	  the	  ALS	  cases.	  All	  CTE+MND	  and	  ALS	  cases	  displayed	  p62	  immunoreactivity	  with	  a	  roughly	  similar	  distribution	  of	  severity.	  11	  of	  12	  CTE+MND	  cases	  and	  9	  of	  10	  ALS	  cases	  displayed	  positive	  cystatin	  C	  immunoreactivity,	  again	  with	  a	  roughly	  similar	  distribution	  of	  pathology	  severity	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between	  the	  two	  diseases.	  No	  single	  CTE+MND	  or	  ALS	  case	  lacked	  immunoreactivity	  across	  all	  of	  the	  evaluated	  stains.	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Figure 1: Images of AT8 (stains for tau) and TDP-43 Pathology Staging. AT8 (left 
column) and TDP-43 (right column) 
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Figure 2: Images of FUS and p62 pathology staging. FUS (left column) and p62 
(right column).  
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Figure 3: Images of Cystatin C pathology staging. Mild stage (+) Cystatin 
C pathology was not found in any of the cases analyzed.  
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DISCUSSION 
Tau Pathology 
 Tau is a microtubule binding protein that promotes stability within neurons. The 
most prominent difference between the CTE+MND and ALS slides was the presence of 
tau pathology in the spinal cord of one-third of the subjects with CTE+MND. This result 
combined with the absence of tau pathology in the ALS cases makes sense intuitively as 
tau pathology is a hallmark feature of CTE and is absent or extremely rare in ALS 
(McKee et al., 2010). While the data set is limited, the results suggest a moderate 
association between CTE stage and severity of tau immunoreactivity within the 
CTE+MND cases. The two lower stage CTE cases (both stage 2) had mild and moderate 
tau pathology grades, while the two higher stage CTE cases, one stage 3 and one stage 4, 
had severe and moderate tau pathology, respectively. The two lower stage tau-positive 
CTE+MND cases were also younger in age at death (31 and 41 years of age compared to 
62 and 66 years of age), which may be explained by the progressive nature of tau 
pathology in CTE. However, none of these associations yet reach statistical significance, 
and more subjects are required to determine if these trends hold up.  
More clinical information such as the number of documented concussions, 
estimated number of sub-concussive hits, and duration of playing career would be 
necessary to tease out any additional explanations for the presence of tau pathology in 
only a fraction of CTE+MND cases. Genetic analysis could also prove useful in 
explaining this discrepancy. Additionally, the prevalence of tau pathology in an age- and 
CTE stage-matched cohort of CTE-only cases would prove valuable in determining 
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whether the presence and distribution of spinal cord tau pathology in CTE+MND cases is 
unique.  
 
TDP-43 Pathology 
 TDP-43 is a protein that binds both DNA and RNA and is involved in 
transcriptional repression, RNA splicing, and translational regulation. 
Hyperphosphorylated TDP-43 is pathologic in nature and has long been a marker for 
neurodegenerative diseases such as ALS and frontotemporal lobar degeneration (Dewey 
et al. 2012). As mentioned previously, a widespread TDP-43 pathology is also associated 
with CTE (McKee et al., 2010, 2013).  
While one CTE+MND case out of twelve lacked TDP-43 pathology, the 
distribution of TDP-43 pathology severity grades among CTE+MND and ALS cases was 
fairly similar. One-third (4 of 12) of CTE+MND cases and 30% (3 of 10) of ALS cases 
displayed mild TDP-43 immunoreactivity. Roughly 40% (5 of 12) of CTE+MND cases 
and 40% (4 of 10) of ALS cases displayed moderate TDP-43 immunoreactivity, while 
roughly 20% (2 of 12) of CTE+MND cases and 30% (3 of 10) of ALS cases displayed 
severe TDP-43 immunoreactivity. Overall, abnormal TDP-43 accumulation in the spinal 
cord mirrors that in sporadic ALS.  
 
FUS Pathology 
Perhaps the second most prominent difference between the CTE+MND and ALS 
cases was observed in each cohort’s distribution of FUS pathology.  FUS is an abundant 
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nuclear protein and performs multiple functions in RNA metabolism, but the role of FUS 
in the nervous system has yet to be fully characterized (Shelkovnikova, 2013). All of the 
CTE+MND cases displayed FUS pathology while FUS immunoreactivity was observed 
in only 8 of 10 ALS cases. While 2 of 12 CTE+MND cases had severe FUS pathology, 
no ALS cases showed more than moderate FUS pathology. However, roughly half of 
CTE+MND and ALS cases showed moderate FUS pathology, so it’s uncertain if the 
absence of severe FUS pathology in the ALS cases is the result of sampling variation. 
While FUS pathology has been associated with ALS (Gordon, 2013), it has not been 
described in CTE. Interestingly, one CTE+MND subject with FUS-positive inclusions 
did not have TDP-43 positivity, suggesting a possible mutation in the FUS gene in this 
individual.  
Because of the cellular role of FUS, it’s entirely possible that FUS pathology is 
secondary to a larger neurodegenerative process. More research needs to be done to help 
illuminate the mechanisms behind pathological FUS protein aggregations and their role 
in neurodegenerative disease.  
 
p62 Pathology 
 Nucleoporin p62 is a multi-domain protein that interacts with the cell’s autophagy 
machinery by helping tag molecules for degradation and it’s abnormal aggregates are 
associated with variants of both ALS and frontotemporal lobar degeneration (Bitto et al., 
2014; Safa, 2011).  
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Very few differences in the distribution and severity of p62 pathology existed 
between CTE+MND and ALS cases. Both diseases showed pathological involvement of 
p62 across all analyzed cases, which could indicate a general disruption in the autophagy 
and protein clearance mechanisms.  
 
Cystatin C Pathology 
Cystatin C is a protein abundant in neural tissue and plays a role in many 
biological functions including modulation of inflammatory responses, cell proliferation 
and growth, and astrocytic differentiation during mouse brain development (Kaur and 
Levy, 2012). Cystatin C is histopathologically linked to ALS as it is one of two known 
proteins that localizes to neuronal inclusions called Bunina bodies within degenerating 
motor neurons (Okamoto et al., 2008). Levels of plasma and cerebrospinal fluid cystatin 
C may also prove to be a promising biomarker for ALS (Wilson et al., 2010).  
Similar to p62, few differences existed in the distribution and severity of cystatin 
C pathology between CTE+MND and ALS cases. A slightly greater number of ALS 
cases (5 of 10) cases than CTE+MND cases (4 of 12) showed severe Cystatin C 
pathology, though this small difference is likely due to random variation. The prevalence 
of Cystatin C pathology in both cohorts suggests a role of general inflammation and cell 
damage in both disease processes.  
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Limitations  
 Brain and spinal cord tissue are particularly limited resources and can be very 
difficult to obtain. This fact, combined with the small number of existing 
neuropathologically verified CTE+MND restricts the usefulness of the associations made 
from the data presented in this study. This pilot study suggests that a cohort of 20-30 
CTE+MND cases along with 20-30 ALS cases will be required to appropriately power 
the analysis for tau staining. It would also be useful to have a better age-matched ALS 
group as 6 of 12 CTE+MND cases were under the age of 49 (with 3 of the 6 below the 
age of 32) while only 2 of 10 ALS cases were under the age of 53 (and none below the 
age of 39).  
 Additionally it will be useful to have a CTE-only comparison group to separate 
out what differences between the CTE+MND and ALS groups could be attributed to CTE 
alone. This would be especially useful for determining whether the tau pathology in the 
CTE+MND was unique in any way and it would help establish a rough baseline 
prevalence for spinal cord tau pathology within the CTE population for comparison.  
 Another factor that likely affected results is the severity of motor neuron cell loss 
within a specific case. Pathology that localizes within a neuron (such as a 
hyperphosphorylated tau neurofibrillary tangle or a TDP-43 inclusion) will be much less 
observed or even absent in the anterior horn of cases with severe motor neuron 
degeneration. For this reason a lack of pathology or a mild severity grade according to the 
metrics used in this study may not be truly representative of the severity of disease.  
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 This analysis was also skewed by the number of spinal cord sections from 
particular level contained on a single slide, which varied from a single section to up to six 
sections for any given case. Pathology grades were not always consistent across all 
sections on a single slide for a particular case and this sampling error was introduced by 
not using a set number of sections from which to make observations. Additionally, it was 
impossible to ensure that all spinal cord tissue was taken from roughly the same level 
from each case. It would be very useful to for future research to analyze representative 
sections at all four levels of the spinal cord (cervical, thoracic, lumbar, and sacral). This 
would not only reduce sampling error but may also help elucidate the mechanisms and 
spread of certain pathological aggregates.  
 
Conclusion and Future Directions 
These results demonstrate that the spinal cord pathology in CTE+MND largely 
parallels that in sporadic ALS.  Both diseases have lower motor neuron inclusions that 
are positive for TDP-43 and FUS.  However, there is a trend towards a greater frequency 
of tau pathology in CTE+MND. An additional fact that may be of importance is the 
discrepancy in that the average age in the CTE+MND cohort (48.4) was substantially less 
than the average age of the ALS cohort (56.9), which could suggest that CTE may 
accelerate the motor neuron degeneration when present.  
The preliminary results discussed in this thesis necessitate a more advanced 
analysis of the spinal cord pathology in CTE+MND with additional CTE control cases 
and a better age-matched ALS cohort. A larger sample size and analysis of all levels of 
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spinal cord with a consistent number of sections from each level will refine and expand 
these results. It would also be useful to examine pathology within the motor cortex to 
examine if any relationships exist between brain and spinal cord pathology within each 
disease. Additionally, it would be very useful to gather in depth clinical data for all cases 
analyzed, including but not limited to information on symptom severity and onset, 
athletic history, history of head trauma, and genetic background.  
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